|

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

RECRUITINGSponsored by University of Southern California
Actively Recruiting
SponsorUniversity of Southern California
Started2026-03-12
Est. completion2027-03-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT07339254

Summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* \* Age ≥ 18 years.
* \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion Criteria:

* \* Patients is unable to consent for themselves
* \* Patient has not yet completed the 1st cycle of ICI-based therapy

Conditions3

CancerLung CancerLung Non-Small Cell Carcinoma

Locations2 sites

Los Angeles General Medical Center
Los Angeles, California, 90033
Sandy Tran323-865-3000sandy.tran@med.usc.edu
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Sandy Tran323-865-3000sandy.tran@med.usc.edu

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.